MF Researcher Database

Researchers Database

Advance

YASUKAWA Tsutomu

    Graduate School of Medical Sciences Department of Ophthalmology and Visual Science　Professor
Contact： yasukawamed.nagoya-cu.ac.jp
Last Updated :2024/04/24

Researcher Information

J-Global ID

Profile

  • 1987-1993 Medical Student, Kyoto University, Faculty of Medicine
    1993-1994 Resident, Department of Ophthalmology, Kyoto University Hospital, Kyoto, Japan
    1994-1996 Resident, Department of Ophthalmology, Kitano Hospital, Osaka, Japan
    1996-2000 PhD Student, Department of Ophthalmology and Visual Sciences,
    Kyoto University Graduate School of Medicine
    2000-2003 Assistant Professor, Department of Ophthalmology and Visual Sciences
    Kyoto University Graduate School of Medicine
    2000-2004 Research fellow, University Eye Hospital Leipzig, Leipzig, Germany
    2004-2005 Clinician, Kurashiki Central Hospital, Okayama, Japan
    2005-2007 Assistant Professor, Department of Ophthalmology and Visual Science
    Nagoya City University Graduate School of Medical Sciences
    2007- Associate Professor, Department of Ophthalmology and Visual Science
    Nagoya City University Graduate School of Medical Sciences

Research Interests

  • 網膜硝子体疾患   網膜色素上皮   Age-Related Macular Degeneration   Drug Delivery System   Retina   Ophthalmology   

Research Areas

  • Life sciences / Ophthalmology

Academic & Professional Experience

  • 2005/06 - Today  Nagoya City University

Education

  • 1996/04 - 2000/03  京都大学大学院  医学研究科  博士課程
  • 1987/04 - 1993/03  Kyoto University  Faculty of Medicine
  • 1983/04 - 1986/03  大阪府立天王寺高校

Association Memberships

  • 日本眼循環学会   日本眼炎症学会   日本眼科AI学会   International Society for Eye Research (ISER)   JAPANESE RETINA AND VITREOUS SOCIETY   Japan Society for Ocular Pharmacology   THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM   Association for Research in Vision and Ophthalmology   JAPANESE OPHTHALMOLOGICAL SOCIETY   

Published Papers

Conference Activities & Talks

  • Autologous Iris Pigment Epithelial Cell Sheet Implants for Chorioretinal Diseases with Retinal Pigment Epithelial Atrophy  [Not invited]
    Tsutomu Yasukawa; Yoshio Hirano; Aki Kato; Yuichiro Ogura
    ARVO 2021  2021/05
  • Iris pigment epithelial cell-sheet transplantation for chorioretinal atrophy  [Invited]
    Tsutomu Yasukawa; Yoshio Hirano; Aki Kato; Yuichiro Ogura
    第125回 日本眼科学会総会  2021/04
  • AI・画像解析を用いた黄斑疾患病態理解と予後予測  [Invited]
    安川 力
    2020/10
  • Moat and wall against exudation from refractory retinal aneurysms.  [Invited]
    Yasukawa T
    Retina World Congress E-Live  2020/10
  • Intravitreal tissue plasminogen activator and ranibizumab for subretinal hyperreflective material in eyes with neovascular age-related macular degeneration  [Not invited]
    Tsutomu Yasukawa; Yuichiro Ogura
    Club Jules Gonin  2020/09
  • Activity Monitoring System and Prognosis Prediction for Macular Diseases  [Invited]
    Tsutomu Yasukawa
    第124回 日本眼科学会総会  2020/04
  • Artificial intelligence (AI)-associated detection and monitoring for macular diseases.  [Invited]
    Yasukawa T
    19th EURETINA Congress  2019/09
  • Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for wet age-related macular degeneration with subretinal hyperreflective material.  [Not invited]
    Takeuchi R; Yasukawa T; Kato A; Obayashi T; Kuwayama S; Kuwayama S; Suzuki N; Takase N; Inoue N; Sugitani K; Hirano Y; Yoshida M; Ogura Y
    ARVO 2019  2019/04
  • Impacts of cataract surgery in eyes treated by anti-vascular endothelial growth factor therapy for wet age-related macular degeneration on visual outcomes.  [Not invited]
    Obayashi T; Yasukawa T; Takeuchi R; Inagaki M; Suzuki K; Takase N; Inoue N; Kato A; Morita H; Hirano Y; Nozaki M; Yoshida M; Ogura Y
    ARVO 2019  2019/04
  • Psychological impact of treat-and-extend ranibizumab therapy in patients with age-related macular degeneration.  [Not invited]
    Kuwayama S; Kato A; Yasukawa T; Sugita I; Yoshida M; Nozaki M; Hirano Y; Kondo J; Abe T; Sugita K; Okita T; Morita H; Sugitani K; Inoue N; Takase N; Ogura Y
    ARVO 2019  2019
  • Twenty-four month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study: visual prognosis and rate of complete resolution of macular edema.  [Not invited]
    Inagaki M; Hirano Y; Suzuki N; Yasuda Y; Kawamura M; Yasukawa T; Yoshida M; Ogura Y
    ARVO 2019  2019
  • Kuwayama S, Kubota F, Kato A, Gomi F, Takagi S, Kinoshita T, Ishikawa H, Mitamura Y, Kondo M, Iwahashi C, Kurimoto Y, Ogura Y, Yasukawa T.  [Not invited]
    ARVO 2019  2019
  • Intraocular sustained release of antibody using a gas-filled hollow core device.  [Not invited]
    Takase N; Yasukawa T; Kato A; Usui H; Kuwayama S; Ogura Y
    The 34th Congress of APAO  2019
  • Title: Preretinal glial membrane with Rock activation after internal limiting membrane peeling  [Not invited]
    Hideaki Usui; Aki Kato; Noriaki Takase; Soichiro Kuwayama; Tsutomu Yasukawa; Yuichiro Ogura
    The 34th Congress of APAO  2019
  • Mechanism of macular hole closure by internal limiting membrane peeling.  [Not invited]
    Yasukawa T
    Vail Vitrectomy Meeting, 2019  2019/02
  • Automated Detection of Macular Diseases by Optical Coherent Tomography (OCT) and Artificial Intelligence (AI)  [Not invited]
    安川 力
    3rd Japan-Taiwan Vitreoretinal Joint Meeting  2018/11
  • 網膜疾患と人工知能AI  [Not invited]
    安川 力
    第18回眼科臨床機器研究会  2018/10
  • Combination Therapy with Intravitreal Tissue Plasminogen Activator and Ranibizumab  [Not invited]
    TSUTOMU YASUKAWA
    第56回 網膜硝子体学会  2017/12
  • 糖尿病網膜症における 広角インドシアニングリーン蛍光眼底造影  [Not invited]
    安川 力
    第２３回日本糖尿病眼学会  2017/10
  • A possible role of lipid accumulation in Bruch’s membrane in the pathogenesis of age-related macular degeneration  [Not invited]
    安川 力
    XXII Biennial Meeting of the International Society for Eye Research  2016/09
  • A Simple, Lens-Sparing Technique to Treat Persisting Hypotonic Maculopathy Secondary to Large Cyclodialysis  [Not invited]
    安川 力
    EURETINA2016  2016/09
  • Visual outcomes of polypoidal choroidal vasculopathy without prompt treatments  [Not invited]
    安川 力
    Club Jules Gonin 2016  2016/07
  • A New Simple Technique to Treat Persisting Hypotonic Maculopathy Secondary to Wide Cyclodialysis  [Not invited]
    安川 力
    Vail Winter Vitrectomy Meeting  2016/02

MISC

Industrial Property Rights

  • 特願2016-93496:眼科薬物徐放装置  2016年/05/06
    安川 力
  • 特願2018-166417:眼科診断支援装置、眼科診断支援方法、及び眼科診断支援プログラム  
    安川 力

Awards & Honors

  • 2020/04 日本眼科学会 第126回日本眼科学会総会 評議員会指名講演（2022発表予定）
  • 2020/01 ベストドクターズ社 Best Doctors in Japan2020-2021
  • 2019/03 Asia-Pacific Academy of Ophthalmology (APAO) Asia-Pacific Academy of Ophthalmology (APAO) Achievement Award
  • 2018/01 Best Doctors, Inc. Best Doctors in Japan2018-2019
     
    受賞者: TSUTOMU YASUKAWA
  • 2008/12 Japanese Retina and Vitreous Society 1st Young Investigator’s Award
     
    受賞者: TSUTOMU YASUKAWA
  • 2003/04 Association for Research in Vision and Ophthalmology Travel Grant for Annual Meeting Association for Research in Vision and Ophthalmology
     
    受賞者: TSUTOMU YASUKAWA
  • 2000/12 フンボルト財団 留学助成
     
    受賞者: 安川 力
  • 2000/04 日本アイバンク協会 留学助成
     
    受賞者: 安川 力

Research Grants & Projects

  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2022/04 -2025/03 
    Author : 安川 力; 野崎 実穂; 平原 修一郎; 小椋 俊太郎; 平野 佳男; 加藤 亜紀
  • 日本学術振興会：科学研究費助成事業
    Date (from‐to) : 2021/04 -2024/03 
    Author : 加藤 亜紀; 安川 力
     
    2021年度は、in vitroにおいて、網膜色素上皮(RPE)スフェロイドの作成を行った。 従来使用していた、ドイツアイバンクからの細胞提供、企業からのprimary RPEの購入ができなかったため、種々の細胞を試した。ヒトテロメア逆転写酵素（hTERT; Human Telomerase Reverse Transcriptase）遺伝子を初代培養細胞に導入して作製したRPEを培養、各種染色、スフェロイド作成を行ったところ、従来のRPE細胞で作成したものと同じスフェロイドの作成が可能であったため、hTERT-RPEを本研究に用いることにした。RPEの通常の培養過程、およびスフェロイド生成過程のタイムラプス撮影を行った。タイムラプス撮影において、RPEは早期から、凝集し始め１時間程度で塊となり、12時間後には凝集し、その後ゆっくりサイズが小さくなることを発見した。 同時にコラーゲンやエラスチンの免疫染色も行い、各種たんぱく質の発現が従来のRPEと同じように発言していることを確認した。
    In vivoにおいては、ヒト高齢者の眼球組織において、眼球の各部位（黄斑部、耳側、鼻側）に分割して網脈絡膜のフラットマウントを作成した。ZO-1で免疫染色を行い、細胞の境界を可視化した。細胞は報告されているように6角形をしていた。得られた標本から、細胞密度、および細胞面積のばらつきを評価する方法を検討した。画像の二値化とボロノイ法の数式を用いてRPEの密度および大きさのむらを数値化することに成功した。フラットマウント標本の評価を行ったところ、黄斑部の細胞密度は周辺部より小さく、ムラも少ない傾向があることを発見した。
  • 日本学術振興会：科学研究費助成事業
    Date (from‐to) : 2021/04 -2024/03 
    Author : 平野 佳男; 安川 力; 鈴木 識裕
     
    本年度は網膜静脈閉塞症(RVO)患者の前房水中の血管内皮増殖因子(VEGF)、アンジオポエチン(Ang)、炎症性サイトカインの発現を確認するために、RVO患者の前房水採取をおこなった。前房水採取は、患者より同意を取得した後、黄斑浮腫に対するVEGF阻害薬投与時に、薬剤投与前に行った。前房水採取にはニプロ社の30ゲージ房水ピペットを用いた。また、同一症例において、黄斑浮腫を光干渉断層計(OCT)で定量した。網膜虚血の定量は、黄斑部の網膜虚血面積は光干渉断層血管撮影(OCTA)で定量し、網膜中間周辺部までの網膜虚血の定量は超広角フルオレセイン蛍光眼底画像(FA)を用いた。さらには、網膜虚血部位の網膜感度をMP-3を用いて網膜虚血部位の機能評価をおこなった。 また、C57BL/6雄マウスを用い、実験的なRVOモデルを作成した。散瞳薬を点眼後、麻酔を行い、ローズベンガルを腹腔内に投与後、眼底観察を行い、視神経乳頭に光凝固を施行し、視神経乳頭上の網膜中心静脈を閉塞させた。その後、眼底観察を行うと、網膜出血、網膜浮腫が認められ、FAでは網膜無灌流領域を確認することが出来、CRVOモデルマウスとした。ただし、レーザーの条件次第では網膜出血、網膜浮腫が出現しないことも多く、モデルマウスを安定して作成できるように努めた。
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2019/04 -2022/03 
    Author : Yasukawa Tsutomu
     
    Intravitreal injections of anti-vascular growth factor drugs, the standard treatment for age-related macular degeneration and other macular diseases, often last for several years, making it difficult for the elderly to continue treatment. As a drug delivery system (DDS) to solve this problem, we are developing a new DDS formulation in which a hollow-core device is filled with lyophilized drug and expansile gas. An acrylic glaucoma implant-type device was implanted in a pigmented rabbit eye, and the released portion was retained intraocularly, showing sustained antibody release over six months. Next, we are developing a encircling buckling-type device used in retinal detachment surgery, because larger inner volume is available for DDS. Teflon was hard and silicone had high gas permeability. Other material will be sought.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2018/04 -2021/03 
    Author : Yuichiro Ogura
     
    In diabetic retinopathy, dropout of pericytes from retinal capillary walls evokes vascular hyperpermeability. Furthermore, progression of vessel obstruction leads to the formation of fibrovascular membranes, which create blinding conditions including retinal detachment. In the present study, by exploiting a pericyte-deficient retinopathy mouse model, we have elucidated that remaining pericytes and retinal pigment epithelium cells transdifferentiate into myofibroblasts, and activated microglia promotes fibrosis during the transition from acute to chronic inflammation. This machinery may underlie the fibrovascular membrane formation in human diabetic retinopathy.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2016/04 -2019/03 
    Author : Nozaki Miho
     
    We evaluated the efficacy of anti-CCR3 treatment in mouse oxygen-induced retinopathy model. In OIR mouse retina, CCR3 and eotaxin were significantly up-regulated. And intravitreous injection of anti-CCR3 antibody suppressed retinal neovascularization, and VEGF 164 mRNA but not VEGF120 mRNA. We also studied the fibrovascular membrane which was surgically excised during vitrectomy in proliferative diabetic retinopathy eyes. In vascular endothelial cells, CCR3 and eotaxin were found in the fibrovascular membrane, but not in epiretinal membrane. From our studies, we demonstrated that CCR3-eotaxin pathway contributes to retinal angiogenesis, and that anti-CCR3 antibody treatment suppressed retinal neovascularization. Anti-CCR3 treatment may have potential as a new therapy for proliferative retinopathies such as diabetic retinopathy and retinopathy of prematurity.
  • 加齢黄斑変性の病態におけるブルッフ膜への加齢性沈着脂質の役割の解明
    日本学術振興会：基盤研究C
    Date (from‐to) : 2016/04 -2019/03 
    Author : 安川 力
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2015/04 -2018/03 
    Author : Hirano Yoshio
     
    Age-related macular degeneration (AMD) is a vision-threatening disease and the number of patients continues to grow. Recently developed anti-vascular endothelial growth factor (VEGF) therapy for choroidal neovascularization (CNV) has revolutionized the treatment in visual improvement. However, there are still ineffective cases or most of the patients need multiple injections of anti-VEGF agents. We aimed to elucidate the pathophysiology of CNV using mouse laser CNV model to investigate a new target for CNV. Inflammation and apoptosis were associated with the CNV formation. Therefore, to control inflammation and apoptosis chould be an alternative therapy to suppress vision loss associated with CNV in AMD.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2015/04 -2018/03 
    Author : AKI KATO
     
    Human retinal pigment epithelium (RPE) cells were cultured without growth factor. For making spheroids, human RPE cells were trypsinized, collected, and resuspended with methylcellulose solution in round-bottom culture plate. Spheroids were collected every day and fixed in in 4% paraformaldehyde, thereafter, the expression of actin was evaluated by immunohistochemistry. Suspended human RPE cells with methylcellulose solution in round-bottom culture plate has been imaged in long-term time-lapse movies over 48 hours. The shape and size of spheroids were analyzed at each time point. The effect of Rho-associated kinase (Rho-kinase) inhibitor for spheroids was evaluated by time-lapse imaging and expression of associated protein.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2015/04 -2018/03 
    Author : Ogura Yuichiro; Koh Gou Young; Kim Pilhan
     
    In diabetic retinopathy (DR), dropout of pericytes from capillary walls is assumed to initiate various vascular dysfunctions, including blood-retina barrier breakdown. However, hyperglycemic mice fail to reproduce retinal pathology characteristic of DR. In this research project, we established a new mouse model of DR in adult mice, by transiently inhibiting pericyte recruitment to developing retinal vessels during neonatal periods following single intraperitoneal injections of an anti-PDGFRβ antibody. Furthermore, we uncovered that endothelial cells and macrophages formed a cycle of vessel damage via VEGF-A, PlGF, and angiopoietin-2 in pericyte-deficient retinal vessels.
  • 抗体および生理活性物質の眼内ドラッグデリバリーシステムの開発
    日本学術振興会：基盤研究C
    Date (from‐to) : 2013/04 -2016/03 
    Author : 安川 力
  • 異常眼底自発蛍光の病理学的意義と加齢黄斑変性発症との関連性の検討
    日本学術振興会：基盤研究C
    Date (from‐to) : 2009/04 -2012/03 
    Author : 安川 力
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2009 -2012 
    Author : OGURA Yuichiro; YASUKAWA Tsutomu; NOZAKI Miho; MATSUBARA Akihisa
     
    Previous studies have shown that siRNAs could suppress angiogenesis via stimulation of toll-like receptor (TLR) -3. The purpose of this study was to determine the efficacy of atelocollagen to deliver siRNA without TLR3 stimulation in the laser-induced choroidal neovascularization (CNV) model. The mean CNV volumes were significantly smaller in the naked siRNA-Luc, naked siRNA-Vegfa, or siRNA-Vegfa /atelocollagen complex compared with PBS, atelocollagen, or siRNA-Luc/atelocollagen complex-injected mice (p < 0.05). These findings demonstrate that atelocollagen may deliver siRNA without non-specific TLR3 stimulation in the murine laser-CNV model.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2009 -2011 
    Author : NOZAKI Miho; OGURA Yuichiro; YASUKAWA Tsutomu
     
    Osteopontin(OPN) is a chemokine like phospholyrated glycoprotein and involved in inflammation, tumor genesis and wound healing. The purpose of the study was to clarify a role of OPN in the development of laser-induced choroidal neovascularization(CNV) in mice. OPN neutralizing Abs significantly abolished CNV area. Genetic ablation of OPN also significantly suppressed CNV area compared with wild-type mice. OPN was immunopositive in the CNV lesions and co-localized with infiltrated macrophages. Collectively these findings demonstrate a significant role of OPN in the development of CNV. OPN blockade may be considered further therapeutic potential for age-related macular degeneration.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2007 -2008 
    Author : NOZAKI Miho; OGURA Yuichiro; SAKURAI Eiji; YASUKAWA Tsutomu
     
    なぜ加齢黄斑変性は黄斑部にのみ脈絡膜新生血管が発生するのか?なぜ黄斑部(中心窩)は無血管なのか?血管新生内皮増殖因子(VEGF-A)を血管新生促進あるいは抑制に働かせるスイッチの働きを持つSPARC に着目し、マウスレーザー誘導実験的脈絡膜新生血管モデルを用いて検討した。レーザー照射後、SPARCの投与により、血管新生は有意に促進され、黄斑部における血管新生促進作用にSPARCが関与しており、今後加齢黄斑変性の治療ターゲットになりうると考えられた
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2006 -2008 
    Author : YASUKAWA Tsutomu; OGURA Yuichiro; SAKURAI Eiji
     
    加齢黄斑変性は成人失明の主要原因である。加齢現象を理解することは病態解明や疾患予防につながるものである。最初の加齢変化は網膜色素上皮細胞内へのリポフスチンと呼ばれる難溶性顆粒の蓄積であるが、本研究では、リポフスチンの成分である最終糖化産物の形成反応により人工的に作製したリポフスチン模擬微粒子を家兎の網膜下に移植することにより、リポフスチン蓄積モデルを作製した。本モデルは加齢黄斑変性の病態を再現しており加齢黄斑変性の病態解明に有用であると考えられた。
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2006 -2008 
    Author : OGURA Yuichiro; YOSHIDA Munenori; SAKURAI Eiji; YASUKAWA Tsutomu
     
    加齢黄斑変性は成人失明の主要原因である。これまで光線力学的療法が標準的な治療法であったが最近、抗血管内皮増殖因子(VEGF)療法の有効性が欧米で示され、国内でも治療の選択肢となってくるが、4~6週間ごとの硝子体内注射を必要とするため合併症が懸念される。注射回数を減らして有効濃度を保てるようなドラッグデリバリーシステムの開発のため、ゼラチンハイドロゲルシートを作製したところ、ポリイオンコンプレックスを形成して抗体を結合できることがわかった。またsiRNAを産生するプラスミドをマウスの静脈内に大量投与すると網膜内に導入可能であることがわかった。VEGF発現に関与しているICAM-1の発現を抑えるsiRNA導入で培養細胞におけるICAM-1の発現を抑制することができた。今後、大型動物における抗VEGF抗体の徐放試験、siRNA導入試験を進めていく。
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 1998 -2000 
    Author : HONDA Yoshihito; TABATA Yasuhiko; KIRYU Junichi; NAKAGAWA Shizue; YASUKAWA Tsutomu
     
    Angiogenesis plays an important role in pathological conditions such as tumor growth, metastasis and inflammation as well as in physiological development and processes such as wound repair. In the eye, choroidal neovascularization (CNV) is a major complication of age-related macular degeneration (AMD), which often causes severe visual loss among the elderly in developed countries. Laser photocoagulation, submacular surgery and radiation have been used for the treatment of AMD.However, no satisfactory therapy has been established clinically to repair visual function. On the other hand, the effects of several anti-angiogenic agents such as interferon alpha, thalidomide, and TNP-470 have been described. However, systemic administration of these drugs has been shown to produce no real benefit for patients with AMD, because these drugs do not have organ-specific affinity and their in vivo half-life is too short. The pharmaceutical modification of drugs results in advantages over the use of free drugs, which makes selective delivery of these drugs to the targeted tissue lead to the use of smaller doses for treatment and result in a reduction in undesirable side effects. We have already demonstrated the efficacy that passive targeting of the anti-angiogenic agents such as TNP-470 and interferon beta against experimental CNV through chemical conjugation with water-soluble polymer might be beneficial in the treatment of experimental CNV.Moreover, recent works in our laboratory have indicated that monoclonal antibodies might be useful as a mediator for active drug targeting to the endothelial cells in experimental CNV. The objective of our study is to investigate the drug delivery system by means of the pharmaceutical modification of drugs and to develop new therapeutic methods of human ocular diseases.

Other link

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.